Continuation of Research and Development Activities
First written in FY2016-Q4. 28 of 35 entries say "Restated". Latest entry: FY2026.
45 other companies' latest entry also says "Other".
- FY2026Shifting R&D priorities to biomanufacturing, AI and new businessesAnnual report
「During the consolidated fiscal year, the Company developed further high-throughput analysis technologies and refined metabolic simulation technologies for its bio-manufacturing support services, while promoting technology development for new businesses. It also worked on development to improve productivity through the use of AI. Total R&D expenses for the consolidated fiscal year were ¥125.109 million.」
The focus of R&D was defined as high-speed analysis and metabolic simulation for bio-manufacturing, new businesses, and productivity improvements through the use of AI. - 2026-08-20AdvancedEarnings presentation
「Development of internal processes to improve R&D productivity」
In addition to continuing research and development, the company reported the development of internal processes aimed at improving productivity. - FY2026-H1Explicitly shifting development priorities to biomanufacturing and new servicesAnnual report
「In R&D, the Company continued developing services for bio-manufacturing support and also worked on developing new services.」
The Company specifically identified bio-manufacturing support services and new services as R&D targets. R&D expenses were ¥55.272 million, down from ¥89.714 million in the same period of the previous year. - FY2024RestatedAnnual report
「During the consolidated fiscal year, the Company advanced R&D primarily in technology development for the comprehensive support service for functional material development, technology development for a new metabolome analysis service, and the development and research of new services. Total R&D expenses for the consolidated fiscal year were ¥181.490 million.」
R&D continued on functional material development support, the new metabolome analysis service and new services. R&D expenses decreased from ¥185.615 million in the previous fiscal year to ¥181.490 million. - FY2024-Q3RestatedAnnual report
「R&D expenses for the cumulative third-quarter consolidated period were ¥136.310 million. There were no significant changes in the status of the Group's R&D activities during the cumulative third-quarter consolidated period.」
R&D expenses of ¥136.310 million were recorded, with no significant changes in the status of R&D activities. - FY2024-Q2RestatedAnnual report
「R&D expenses for the cumulative second-quarter consolidated period were ¥95.923 million. There were no significant changes in the status of the Group's R&D activities during the cumulative second-quarter consolidated period.」
R&D expenses of ¥95.923 million were recorded, with no significant changes in the status of R&D activities. - FY2024-Q1RestatedAnnual report
「R&D expenses for the cumulative first-quarter consolidated period were ¥41.791 million. There were no significant changes in the status of the Group's R&D activities during the cumulative first-quarter consolidated period.」
R&D expenses of ¥41.791 million were recorded, with no significant changes in the status of R&D activities. - FY2023AdvancedAnnual report
「During the consolidated fiscal year, the Company advanced R&D primarily in technology development for the comprehensive support service for functional material development, technology development for a new metabolome analysis service, R&D toward the practical application and commercialization of mental health biomarkers, and the development and research of new services. Total R&D expenses for the consolidated fiscal year were ¥185.615 million.」
R&D was expanded to support functional material development, the new metabolome analysis service, mental health biomarkers and new services, bringing R&D expenses to ¥185.615 million. - FY2023-Q3RestatedAnnual report
「R&D expenses for the cumulative third-quarter consolidated period were ¥133.219 million. There were no significant changes in the status of the Group's R&D activities during the cumulative third-quarter consolidated period.」
R&D expenses of ¥133.219 million were recorded, with no significant changes in the status of R&D activities. - FY2023-Q2RestatedAnnual report
「R&D expenses for the cumulative second-quarter consolidated period were ¥84.770 million. There were no significant changes in the status of the Group's R&D activities during the cumulative second-quarter consolidated period.」
R&D expenses of ¥84.770 million were recorded, with no significant changes in the status of R&D activities. - FY2023-Q1RestatedAnnual report
「R&D expenses for the cumulative first-quarter consolidated period were ¥42.172 million. There were no significant changes in the status of the Group's R&D activities during the cumulative first-quarter consolidated period.」
R&D expenses for the quarter were ¥42.172 million, with no significant changes in the status of R&D activities. - FY2022AdvancedAnnual report
「During the consolidated fiscal year, the Company advanced R&D primarily in technology development for a new metabolome analysis service, product development toward the practical application and commercialization of PEA, and the development and research of new services. Total R&D expenses for the consolidated fiscal year were ¥158.289 million.」
The Company advanced technology development for the new service and R&D on PEA products and new services. R&D expenses were ¥158.289 million, up from ¥98.224 million in the previous fiscal year. - FY2022-Q3RestatedAnnual report
「R&D expenses for the cumulative third-quarter consolidated period were ¥99.572 million. There were no significant changes in the status of the Group's R&D activities during the cumulative third-quarter consolidated period.」
R&D expenses of ¥99.572 million were recorded, with no significant changes in the status of R&D activities. - FY2022-Q2RestatedAnnual report
「R&D expenses for the cumulative second-quarter consolidated period were ¥62.981 million. There were no significant changes in the status of the Group's R&D activities during the cumulative second-quarter consolidated period.」
R&D expenses of ¥62.981 million were recorded, with no significant changes in the status of R&D activities. - FY2022-Q1RestatedAnnual report
「R&D expenses for the cumulative first-quarter consolidated period were ¥26.261 million. There were no significant changes in the status of the Group's R&D activities during the cumulative first-quarter consolidated period.」
R&D expenses of ¥26.261 million were recorded, with no significant changes in the status of R&D activities. - FY2021RestatedAnnual report
「During the consolidated fiscal year, the Company advanced R&D primarily in the development of core technologies for metabolome analysis, product development toward the practical application and commercialization of PEA, and exploratory research into new biomarkers. Total R&D expenses for the consolidated fiscal year were ¥98.224 million.」
R&D continued on core technologies, PEA products and new biomarkers. R&D expenses were ¥98.224 million, down from ¥155.558 million in the previous fiscal year. - FY2021-Q3RestatedAnnual report
「R&D expenses for the cumulative third-quarter consolidated period were ¥78.181 million. There were no significant changes in the status of the Group's R&D activities during the cumulative third-quarter consolidated period.」
R&D expenses of ¥78.181 million were recorded, with no significant changes in the status of R&D activities. - FY2021-Q2RestatedAnnual report
「R&D expenses for the cumulative second-quarter consolidated period were ¥52.139 million. There were no significant changes in the status of the Group's R&D activities during the cumulative second-quarter consolidated period.」
R&D expenses of ¥52.139 million were recorded, with no significant changes in the status of R&D activities. - FY2021-Q1RestatedAnnual report
「R&D expenses for the cumulative first-quarter consolidated period were ¥25.166 million. There were no significant changes in the status of the Group's R&D activities during the cumulative first-quarter consolidated period.」
R&D expenses of ¥25.166 million were recorded for the first quarter, with no significant changes in the status of R&D activities. - FY2020RestatedAnnual report
「During the consolidated fiscal year, the Company advanced R&D primarily in the development of core technologies for metabolome analysis, product development toward the practical application and commercialization of PEA, and exploratory research into new biomarkers. Total R&D expenses for the consolidated fiscal year were ¥155.558 million.」
R&D continued on core technologies, PEA products and new biomarkers, and R&D expenses of ¥155.558 million were recorded. - FY2020-Q3RestatedAnnual report
「R&D expenses for the cumulative third-quarter consolidated period were ¥117.840 million. There were no significant changes in the status of the Group's R&D activities during the cumulative third-quarter consolidated period.」
R&D expenses of ¥117.840 million were recorded for the cumulative third-quarter period, with no significant changes in the status of R&D activities. - FY2020-Q2RestatedAnnual report
「R&D expenses for the cumulative second-quarter consolidated period were ¥70.297 million. There were no significant changes in the status of the Group's R&D activities during the cumulative second-quarter consolidated period.」
R&D expenses of ¥70.297 million were recorded, with no significant changes in R&D activities. - FY2020-Q1RestatedAnnual report
「R&D expenses for the cumulative first-quarter consolidated period were ¥33.945 million. There were no significant changes in the status of the Group's R&D activities during the cumulative first-quarter consolidated period.」
R&D expenses of ¥33.945 million were recorded for the first quarter, with no significant changes in R&D activities. - FY2019RestatedAnnual report
「During the consolidated fiscal year, the Company advanced R&D primarily in the development of core technologies for metabolome analysis, product development toward the practical application and commercialization of PEA, and exploratory research into new biomarkers. Total R&D expenses for the consolidated fiscal year were ¥189.684 million.」
R&D continued on core technologies, PEA products and new biomarkers, and R&D expenses of ¥189.684 million were recorded. - FY2019-Q3RestatedAnnual report
「R&D expenses for the cumulative fourth-quarter consolidated period were ¥156.484 million. There were no significant changes in the status of the Group's R&D activities during the cumulative fourth-quarter consolidated period.」
R&D expenses of ¥156.484 million were recorded, with no significant changes in the status of R&D activities. - FY2019-Q2RestatedAnnual report
「R&D expenses for the cumulative third-quarter consolidated period were ¥124.439 million. There were no significant changes in the status of the Group's R&D activities during the cumulative third-quarter consolidated period.」
R&D expenses of ¥124.439 million were recorded, with no significant changes in the status of R&D activities. - FY2019-Q1RestatedAnnual report
「R&D expenses for the cumulative second-quarter consolidated period were ¥76.447 million. There were no significant changes in the status of the Group's R&D activities during the cumulative second-quarter consolidated period.」
R&D expenses of ¥76.447 million were recorded, with no significant changes in the status of R&D activities. - FY2018-Q4RestatedAnnual report
「R&D expenses for the cumulative first-quarter consolidated period were ¥46.183 million. There were no significant changes in the status of the Group's R&D activities during the cumulative first-quarter consolidated period.」
R&D expenses of ¥46.183 million were recorded for the first quarter, with no significant changes in the status of R&D activities. - FY2018-Q2RestatedAnnual report
「R&D expenses for the cumulative third-quarter consolidated period were ¥182.717 million. There were no significant changes in the status of the Group's R&D activities during the cumulative third-quarter consolidated period.」
R&D expenses of ¥182.717 million were recorded, with no significant changes in the status of R&D activities. - FY2018-Q1RestatedAnnual report
「R&D expenses for the cumulative second-quarter consolidated period were ¥125.410 million. There were no significant changes in the status of the Group's R&D activities during the cumulative second-quarter consolidated period.」
R&D expenses of ¥125.410 million were recorded, with no significant changes in the status of R&D activities. - FY2017-Q4RestatedAnnual report
「R&D expenses for the cumulative first-quarter consolidated period were ¥51.380 million. There were no significant changes in the status of the Group's R&D activities during the cumulative first-quarter consolidated period.」
R&D expenses of ¥51.380 million were recorded for the first quarter, with no significant changes in the status of R&D activities. - FY2017AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥209.861 million.」
R&D expenses increased from ¥139.490 million in the previous consolidated fiscal year to ¥209.861 million, as the Company advanced product development, clinical research and next-generation core technology development. - FY2017-Q2RestatedAnnual report
「R&D expenses for the cumulative third-quarter consolidated period were ¥125.542 million. There were no significant changes in the status of the Group's R&D activities during the cumulative third-quarter consolidated period.」
R&D expenses of ¥125.542 million were recorded, with no significant changes in R&D activities. - FY2017-Q1RestatedAnnual report
「R&D expenses for the cumulative second-quarter consolidated period were ¥73.463 million. There were no significant changes in the status of the Group's R&D activities during the cumulative second-quarter consolidated period.」
R&D expenses of ¥73.463 million were recorded, with no significant changes in R&D activities. - FY2016-Q4First statedAnnual report
「R&D expenses for the cumulative first-quarter consolidated period were ¥39.223 million. There were no significant changes in the status of the Group's R&D activities during the cumulative first-quarter consolidated period.」
R&D expenses of ¥39.223 million were recorded for the quarter, with no significant changes in R&D activities.